Genentech, a member of the Roche Group (RHHBY.PK), said it will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology June 1 to 5, 2012, in Chicago.
At the meeting, data on Genentech's late-stage investigational and approved cancer medicines will be communicated in sessions that include 30 oral presentations.
Trastuzumab emtansine's pivotal Phase III data in people with HER2-positive metastatic breast cancer who had previously received treatment with Herceptin and a taxane (chemotherapy) will be presented for the first time. These data will be submitted to global health authorities later this year. EMILIA will be presented in the plenary session at ASCO and will also be highlighted as part of ASCO's official press program.
Data will be presented from a Phase III study evaluating Avastin in combination with chemotherapy in people with metastatic colorectal cancer, whose disease worsened following initial treatment with Avastin and a different chemotherapy. This study will be highlighted as part of American Society of Clinical Oncology's official press program.
Data from AURELIA, the first Phase III study of Avastin plus chemotherapy in people with platinum-resistant recurrent ovarian cancer will be presented. This study will be highlighted as part of ASCO's official press program.
Further, updated overall survival results will be presented based on the most recent analysis from BRIM3, a Phase III study of Zelboraf in people with previously untreated BRAF V600E mutation-positive unresectable or metastatic melanoma.
"We have made significant progress for people with advanced cancers in the past year," said Hal Barron, chief medical officer and head, Global Product Development. "At ASCO, we're pleased to present new data showing how we are moving forward in our goal of helping people who need new options in their fight against a number of advanced cancers, including data from EMILIA, our pivotal Phase III study on trastuzumab emtansine in HER2-positive metastatic breast cancer."
For comments and feedback: editorial@rttnews.com